Evidence map›Paper›PMID 21449242›Full record

ArticleThe journal of extra-corporeal technology2011

Blood management-issues: the panic of coagulopathic bleeding--is there a rational approach?

Bruce D Spiess

Abstract read
In one paragraph

Article in The journal of extra-corporeal technology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Bruce D SpiessAnaesthesiology and Emergency Medicine, Virginia Commonwealth University Medical Center, Richmond, Virginia 23298-0662, USA. bdspiess@vcu.edu

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blood management is an evolving field of reducing transfusions of allogeneic blood by maximizing multi-modality therapy to optimize red cell mass, reduce red cell loss, and harvest red cells that would have otherwise been discarded. These techniques are highly dependent upon teams working together. The programs are not just focused upon red cells but also on coagulation therapy. Coagulopathy is at times a difficult complex pathologic conundrum. In cardiac surgery the complexity is added to because of the inflammatory effects of anticoagulation, air/blood interfaces, and inflammation. Patients respond variably due to their own genetic and environmental factors. There can be a rational approach, thereby avoiding panic (a normal fear response) if the clinician utilizes not only the available laboratory technologies existing today but also follows published algorithms for treatment. These technologies with their coexisting algorithms have been widely shown to decrease blood usage, yet not to decrease bleeding. That finding suggests that therapy without such guidance wastes expensive pro-coagulant blood products and produces no advantage (a decrease in bleeding). When a therapy produces no advantage all that it leaves the patient with is the side effects or adverse outcomes. Adverse outcomes from coagulation products are real and sobering.

Indexed as

Blood Coagulation DisordersBlood Coagulation TestsBlood Loss, SurgicalBlood PlateletsCardiopulmonary BypassHematologic AgentsHemorrhageHeparinHumansPlasmaHematologic AgentsHeparin

Identifiers

PMID21449242
PMCPMC4680099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.